ClinicalTrials.gg
TerminatedNCT06049459Updated Nov 6, 2026

Novel Amblyopia Treatment With Virtual Reality Games

An interventional study of Optical Correction and Therapeutic Dichoptic Virtual Reality Games in Amblyopia, sponsored by Marjean Kulp. Terminated at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Marjean Kulp · Not applicable, Interventional, and Treatment

Why this study was terminated
Slower than anticipated recruitment
Updated Nov 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
5 Years to 17 Years
Sex
All
01

Study summary

The goal of this study is to compare the change in amblyopic eye acuity between treatment periods in children with amblyopia, aged 5-17 years. The main question it aims to answer is:

Is a 16-week course of amblyopia treatment using Vivid Vision Therapeutic (Dichoptic) Virtual Reality Games for approx. 25 min/day, 6 days/week more effective for improvement in amblyopic-eye VA, binocularity (stereoacuity, suppression, alignment), contrast sensitivity, attention, oculomotor function, visual-motor integration, and quality of life than 16 weeks of continued glasses alone?

Participants will each serve as their own control and complete:

Treatment period 1: Continued optical correction (glasses) alone for 16 weeks; Treatment period 2: Vivid Vision Therapeutic (Dichoptic) Virtual Reality Games for 16 weeks (approx. 25min/day, 6 days/week) plus continued optical correction

02

Conditions studied

  • Amblyopia

Browse trials for

03

In context

Amblyopia

189 studies on the registry are indexed under Amblyopia; 41 are open to participants now.

This study's enrollment of 3 is below the median of 60 across 137 interventional studies indexed under Amblyopia.

Browse Amblyopia studies →

Lead sponsor

This is the only study on the registry with Marjean Kulp as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients ages 5 to 17 years of age

  • Moderate to severe unilateral amblyopia (logMAR best corrected visual acuity 0.3 to 1.3) associated with anisometropia and/or strabismus of ≤5pd
  • Age normal VA in the nonamblyopic eye
  • Spectacle correction (if required) worn for at least 16 weeks, or until stability of VA is demonstrated (\<0.1 logMAR change by the same testing method measured on 2 exams at least 8 weeks apart)
  • Interocular difference of ≥ 3 lines
  • No amblyopia treatment in the past 2 weeks
  • An interpupillary distance of 52-72 mm (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Myopia greater than -6.00 diopters (D) spherical equivalent in either eye.
  • Previous intraocular or refractive surgery.
  • Previous dichoptic treatment > 2 weeks in duration
  • Ocular co-morbidity that may reduce visual acuity determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above visual acuity criteria are met).
  • Diplopia more than once per week over the last week prior to enrollment by parental report.
  • Down syndrome or cerebral palsy.
  • Light-induced seizures
  • Known simulator sickness
  • Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities are not excluded.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Optical Correction alone

    Optical correction alone (16 weeks) (Each participant will complete both study conditions.)

    Device: Optical Correction

  • Experimental
    Therapeutic (Dichoptic) Virtual Reality Games plus Continued Optical Correction

    Therapeutic (Dichoptic) Virtual Reality Games plus continued optical correction (16 weeks) (Each participant will complete both study conditions.)

    Device: Optical Correction · Device: Therapeutic Dichoptic Virtual Reality Games

Interventions

  • DeviceOptical Correction

    Optical correction (if needed)

  • DeviceTherapeutic Dichoptic Virtual Reality Games

    Virtual Reality Game play for amblyopia treatment

06

What researchers measure

Primary outcomes

  1. Difference in Mean Change in Amblyopic Eye Visual Acuity

    Optical correction worn for testing using Amblyopia Treatment Study (ATS) protocol; HOTV for ages 5-6 years; E-ETDRS for ages 7 years and older

    Time frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

Secondary outcomes

  1. Difference in Change in Stereoacuity/Binocularity

    Optical correction worn for testing. Stereoacuity scores (seconds of arc) calculated based on the Randot Butterfly (scores: 2000, Nil) and Randot Preschool stereoacuity (scores: 800, 400, 200, 100, 60 and 40) tests. Lower scores indicate better stereoacuity. Nil (4000) defined as an incorrect response (or lack of an attempt) on the butterfly without a correct response on 800 seconds of arc level of Randot Preschool stereoacuity test. Stereoacuity scores will be ordered and assigned a rank score. Change in stereoacuity will be calculated as the difference in change in ranked score.

    Time frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

  2. Difference in Mean Change in Amblyopic-Eye Contrast Sensitivity

    Optical correction worn for testing. Spot Checks;Contrast sensitivity scores range from unable (\<0.90), and then from 0.90 to 2.05 (by 0.05 log contrast sensitivity units).

    Time frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

  3. Difference in Mean Change in Attention

    Optical correction worn for testing. The Children's Color Trails Test (CCTT) is a neuropsychological standardized test that measures attention, divided attention, and speed of mental processing.

    Time frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

  4. Difference in Mean Change in reading eye movements

    Optical correction worn for testing with Readalyzer eye tracker.

    Time frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

  5. Difference in Mean Change in visual-motor integration

    Optical correction worn for testing. Beery Visual-Motor Integration; standard scores with mean of 100, standard deviation of 15

    Time frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

  6. Difference in Mean Change in Pediatric Eye Questionnaire (PedEyeQ)

    Pediatric Eye Questionnaire (PedEyeQ) domain score; scores for questionnaire items will be obtained from published look-up tables available at www.pedig.net; scaled to score from 0 to 100 (worst to best)

    Time frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Recruiting→Terminated Slower than anticipated recruitment
changed Nov 6, 2026
Primary completion
Dec 31, 2026→Jul 29, 2026 (actual)
Nov 6, 2026
Study completion
Dec 31, 2026→Jul 29, 2026 (actual)
Nov 6, 2026
Enrollment
8 (estimated)→3 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Terminated
    Why stopped Slower than anticipated recruitment
    Primary completion Dec 31, 2026→Jul 29, 2026 (now actual)
    Study completion Dec 31, 2026→Jul 29, 2026 (now actual)
    Enrollment 8 (estimated)→3 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06049459
Lead sponsor
Marjean Kulp
Collaborators
Beta Sigma Kappa - College of Optometrists in Vision Development, VividVision
Responsible party
Marjean Kulp (Professor, Ohio State University) — Sponsor-investigator
First posted
Sep 22, 2023
Start date
Mar 14, 2024
Primary completion
Jul 29, 2026
Completion
Jul 29, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion